A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
Massachusetts General Hospital
Dana-Farber Cancer Institute
University of Miami
Eastern Cooperative Oncology Group
Regeneron Pharmaceuticals
University of Utah
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
University of Rochester
Regeneron Pharmaceuticals
Seoul National University Bundang Hospital
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center